ES2542842T3 - Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer - Google Patents
Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer Download PDFInfo
- Publication number
- ES2542842T3 ES2542842T3 ES02252414.4T ES02252414T ES2542842T3 ES 2542842 T3 ES2542842 T3 ES 2542842T3 ES 02252414 T ES02252414 T ES 02252414T ES 2542842 T3 ES2542842 T3 ES 2542842T3
- Authority
- ES
- Spain
- Prior art keywords
- transfer agent
- taurultam
- taurolidine
- administered
- methylol transfer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
El uso de un agente de transferencia de metilol en la fabricación de un medicamento para uso en la inducción de la muerte apoptótica de una célula neoplásica en un mamífero poniendo en contacto dicha célula con una cantidad inductora de apoptosis de dicho medicamento, en el que dicho medicamento es para ser administrado durante al menos dos ciclos de administración, incluyendo cada ciclo de administración (i) una fase de administración de 1 a 8 días durante la cual dicho medicamento se administra cada día a una dosis diaria total de 2 a 60 g de dicho agente de transferencia de metilol y (ii) una fase sin administración de 1 a 14 días, durante la cual no se administra agente de transferencia de metilol, en el que el agente de transferencia de metilol es taurolidina, taurultam o una mezcla de los mismos.
Description
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28074801P | 2001-04-03 | 2001-04-03 | |
US280748P | 2001-04-03 | ||
US28171301P | 2001-04-06 | 2001-04-06 | |
US28171001P | 2001-04-06 | 2001-04-06 | |
US28171201P | 2001-04-06 | 2001-04-06 | |
US28171101P | 2001-04-06 | 2001-04-06 | |
US281711P | 2001-04-06 | ||
US281712P | 2001-04-06 | ||
US281713P | 2001-04-06 | ||
US281710P | 2001-04-06 | ||
US28493301P | 2001-04-20 | 2001-04-20 | |
US28493401P | 2001-04-20 | 2001-04-20 | |
US284934P | 2001-04-20 | ||
US284933P | 2001-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2542842T3 true ES2542842T3 (es) | 2015-08-12 |
Family
ID=27569569
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02252414.4T Expired - Lifetime ES2542842T3 (es) | 2001-04-03 | 2002-04-03 | Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer |
ES10009649.4T Expired - Lifetime ES2562827T3 (es) | 2001-04-03 | 2002-04-03 | Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10009649.4T Expired - Lifetime ES2562827T3 (es) | 2001-04-03 | 2002-04-03 | Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer |
Country Status (5)
Country | Link |
---|---|
US (1) | US20030027818A1 (es) |
EP (2) | EP2258373B1 (es) |
JP (2) | JP2002363102A (es) |
CA (2) | CA2692295C (es) |
ES (2) | ES2542842T3 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US20070275955A1 (en) * | 1997-07-31 | 2007-11-29 | Ed. Geistlich Soehne Ag | Method of treating tumors |
US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
US6821968B2 (en) | 2001-09-26 | 2004-11-23 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Stable taurolidine electrolyte solutions |
US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
AU2002236517A1 (en) * | 2000-11-29 | 2002-06-11 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
US20030092707A1 (en) * | 2001-10-19 | 2003-05-15 | Redmond H. Paul | Treatment of breast cancer |
US20090123428A1 (en) * | 2003-04-21 | 2009-05-14 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
EP2353389B1 (en) * | 2003-04-21 | 2015-11-04 | Epeius Biotechnologies Corporation | Compositions for treating disorders |
US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
US8236794B2 (en) * | 2003-09-29 | 2012-08-07 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of mesothelioma |
PT1957074E (pt) * | 2005-11-29 | 2014-06-25 | Novartis Ag | Formulações de quinolinonas |
US7928102B2 (en) | 2006-01-06 | 2011-04-19 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam |
ES2332864T1 (es) * | 2006-09-07 | 2010-02-15 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Procedimiento para tratar el cancer de hueso. |
WO2011151722A2 (en) * | 2010-06-01 | 2011-12-08 | Geistlich Pharma Ag | Methods and compositions for oral pharmaceutical therapy |
WO2017040655A1 (en) * | 2015-08-31 | 2017-03-09 | Cormedix Inc. | Delivery of active agents using nanofiber webs |
US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
AU2019330954A1 (en) * | 2018-08-28 | 2021-04-22 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
AU2019331913A1 (en) * | 2018-08-31 | 2021-04-29 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
US20220323452A1 (en) * | 2019-05-22 | 2022-10-13 | Geistlich Pharma Ag | Methods and compositions for inhibiting gapdh |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210083A (en) | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
GB8617482D0 (en) | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
GB9005856D0 (en) | 1990-03-15 | 1990-05-09 | Geistlich Soehne Ag | Compositions |
GB9015108D0 (en) * | 1990-07-09 | 1990-08-29 | Geistlich Soehne Ag | Chemical compositions |
AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
GB9600426D0 (en) * | 1996-01-10 | 1996-03-13 | Ed Geistlich Sohne A G | Compositions |
US5858990A (en) * | 1997-03-04 | 1999-01-12 | St. Elizabeth's Medical Center | Fas ligand compositions for treatment of proliferative disorders |
BR9809149A (pt) | 1997-05-20 | 2000-08-01 | Galenica Pharmaceuticals Inc | Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória |
AU734460B2 (en) * | 1997-05-22 | 2001-06-14 | Oklahoma Medical Research Foundation | Use of taurolidine for treatment of leukemias |
GB9716219D0 (en) * | 1997-07-31 | 1997-10-08 | Geistlich Soehne Ag | Prevention of metastases |
US6479481B1 (en) | 1999-06-04 | 2002-11-12 | Ed. Geistlich Soehne Ag Fur Chemische Industrie | Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
ATE339207T1 (de) * | 1999-12-06 | 2006-10-15 | Rhode Island Hospital | Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen |
CA2363973C (en) * | 2000-11-28 | 2009-03-10 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
-
2002
- 2002-03-29 US US10/109,058 patent/US20030027818A1/en not_active Abandoned
- 2002-04-02 CA CA2692295A patent/CA2692295C/en not_active Expired - Lifetime
- 2002-04-02 JP JP2002100404A patent/JP2002363102A/ja active Pending
- 2002-04-02 CA CA2379734A patent/CA2379734C/en not_active Expired - Lifetime
- 2002-04-03 ES ES02252414.4T patent/ES2542842T3/es not_active Expired - Lifetime
- 2002-04-03 ES ES10009649.4T patent/ES2562827T3/es not_active Expired - Lifetime
- 2002-04-03 EP EP10009649.4A patent/EP2258373B1/en not_active Expired - Lifetime
- 2002-04-03 EP EP02252414.4A patent/EP1247524B1/en not_active Expired - Lifetime
-
2009
- 2009-02-03 JP JP2009022892A patent/JP5232678B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2258373B1 (en) | 2016-01-27 |
EP1247524B1 (en) | 2015-06-24 |
ES2562827T3 (es) | 2016-03-08 |
CA2692295A1 (en) | 2002-10-03 |
JP2009138003A (ja) | 2009-06-25 |
US20030027818A1 (en) | 2003-02-06 |
EP1247524A1 (en) | 2002-10-09 |
CA2692295C (en) | 2013-06-25 |
EP2258373A1 (en) | 2010-12-08 |
JP2002363102A (ja) | 2002-12-18 |
CA2379734C (en) | 2010-06-29 |
JP5232678B2 (ja) | 2013-07-10 |
CA2379734A1 (en) | 2002-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2542842T3 (es) | Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer | |
ES2150889T1 (es) | Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii. | |
DOP2022000100A (es) | Agonista del receptor glp-1 y uso de este | |
AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
AR031973A1 (es) | Agonistas de los receptores beta2-adrenergicos, una composicion farmaceutica, y uso de dichos agonistas para la manufactura de un medicamento | |
PA8542701A1 (es) | Composición parenteral reconstituible | |
ES2060199T3 (es) | Forma galenica para administrar oralmente glipicida hipoglicemica. | |
CO6220962A2 (es) | Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina | |
ES2139132T3 (es) | Composiciones farmaceuticas activas en la terapia de desordenes del sueño. | |
AR035863A1 (es) | Ligandos receptores de melanocortina | |
UY26926A1 (es) | Derivados de la quinolina y quinazolina | |
ES2176436T3 (es) | Nueva forma de dosificacion farmaceutica oral. | |
GEP20063799B (en) | Tropane derivatives useful in therapy | |
MX9203444A (es) | Medicamentos. | |
AR020803A1 (es) | Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento | |
UY27296A1 (es) | Composición farmacéutica que contiene mosaprida y pancreatina | |
DK349889D0 (da) | Anvendelse af polyacrylater til fremstilling af et laegemiddel | |
AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
ES2119748T3 (es) | Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua. | |
UY25798A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. | |
CR7049A (es) | Empleo de flumazenilo en la elaboracion de una medicacion para el tratamiento de la dependencia del alcohol | |
AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
RU2003105901A (ru) | Противовоспалительное лекарственное средство | |
MX9304365A (es) | Una forma de dosis osmotica para administrar tandospirona. |